On Thursday, Citi has increased its price target for Zai Lab (NASDAQ:ZLAB) shares to $70.00, up from the previous $66.00, while maintaining a Buy rating. The adjustment follows the presentation of Phase 1 trial results for Zai Lab's experimental drug ZL-1310 at the Triple Meeting, which indicated a high objective response rate (ORR) in small cell lung cancer (SCLC) patients.
The drug, a DLL3 antibody-drug conjugate (ADC), showed a 74% ORR (14 out of 19 patients), with an even more impressive 100% ORR in patients with brain metastases (6 out of 6 patients). These outcomes are particularly notable when compared to Amgen (NASDAQ:AMGN)'s tarlatamab, a DLL3 T-cell engager (TCE) that received accelerated approval earlier this year for SCLC treatment, which demonstrated a 40% ORR and a duration of response (DoR) of 8.7 months.
Citi's analyst highlighted several potential advantages of ZL-1310 over the TCE alternative. These include the possibility of outpatient administration, which could facilitate easier access in community settings, and a different toxicity profile that does not include cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). This safety profile could make ZL-1310 a preferable candidate for combination with anti-PD-L1 therapies in first-line (1L) treatment settings.
The promising initial results for ZL-1310 position Zai Lab favorably in the development of next-generation ADCs for the treatment of SCLC, a disease area where improved therapeutic options are critically needed. The company's ongoing research and development efforts continue to be closely watched by investors and analysts alike.
In other recent news, Zai Lab, a biopharmaceutical company, reported a significant increase in net product revenues during its second-quarter 2024 earnings call, surpassing $100 million for the first time, a 45% year-over-year growth. The successful launch of VYVGART, a treatment for generalized myasthenia gravis, has been a major contributor to this growth. Despite a net loss of $80.3 million for the quarter, the company is optimistic about achieving profitability by the end of 2025, backed by its robust pipeline and strategic initiatives in oncology and immunology.
Zai Lab's pipeline includes new product approvals and advancements in schizophrenia and gastric cancer treatments, with a strong cash position of $730 million. The company plans to focus on patient acquisition and transition to maintenance treatment in the second half of the year, with a projected 50% sales growth from the end of 2023 to the end of 2028.
The launch of subcutaneous VYVGART is planned for later this year, with NRDL coverage expected in 2026. Zai Lab remains focused on driving top-line growth and achieving profitability through efficient expense management and strong revenue growth.
InvestingPro Insights
Zai Lab's recent positive trial results for ZL-1310 align with the company's strong market performance and growth potential. According to InvestingPro data, Zai Lab has demonstrated impressive revenue growth, with a 45.95% increase in quarterly revenue as of Q2 2024. This growth trajectory supports the optimism surrounding the company's drug development pipeline.
InvestingPro Tips highlight that analysts anticipate sales growth in the current year, which is consistent with the promising clinical trial outcomes. Additionally, the company holds more cash than debt on its balance sheet, providing financial flexibility to continue its research and development efforts.
However, investors should note that Zai Lab is not currently profitable, with a negative gross profit margin in the last twelve months. This is not unusual for biotech companies in the development stage, but it underscores the importance of successful drug candidates like ZL-1310 for the company's future profitability.
For those interested in a deeper analysis, InvestingPro offers 13 additional tips for Zai Lab, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.